Michelle Gilson
Stock Analyst at Morgan Stanley
(1.08)
# 3,833
Out of 5,106 analysts
31
Total ratings
32.14%
Success rate
-6.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $6.01 | +232.78% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $85.11 | -64.75% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $2.05 | +729.27% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $209.43 | -6.41% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $36.50 | +23.29% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $33.52 | +126.73% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $59.28 | +53.51% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $6.01
Upside: +232.78%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $85.11
Upside: -64.75%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $2.05
Upside: +729.27%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $209.43
Upside: -6.41%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $36.50
Upside: +23.29%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $33.52
Upside: +126.73%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $59.28
Upside: +53.51%